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Many pharmaceutical systems are essentially made up by a polymeric carrier hosting the active agent (drug) inside its three-dimensional network [1, 2]. Especially in the case of oral administration, they are often prepared as particulate systems since these forms present remarkable advantages over the single unit devices. The easier dispersion inside the stomach reflects into an appreciable reduction of the local drug concentration which is usually responsible for gastric irritation [3]. Moreover, they are very versatile and powerful as drug loading into crosslinked polymers can represent a profitable tool to increase the drug dissolution rate in aqueous media and, thus, the bioavailability of slightly water soluble crystalline drugs [4]. Indeed, for example, by means of solvent swelling, co-grinding techniques or supercritical CO2 [5-7], the drug can be loaded inside the polymeric network in form of macro-crystals, nano-crystals and amorphous state. Interestingly, drug nano-crystals and amorphous state are characterised by increased water solubility (in virtue of their small crystal size, strictly connected to small curvature radii) with respect to macro-crystal and this, obviously, reflects into increased bioavailability [6]. Unfortunately, however, thermodynamically speaking, drug nanocrystals and amorphous state are, usually, far from being stable compared to the lifetime required to a pharmaceutical product (months or years). Accordingly, the addition of at least one more component (stabilizer), usually a polymer, is required. Indeed, drugs can interact, for example, via Van der Waals or hydrogen bonds, with the stabiliser yielding to pharmaceutically stable products conserving their activation for a long time [6]. In addition, in the case of polymeric stabilizers, the physical presence of the polymeric chains hinders macro-crystals formation since macro-crystals can form and grow as long as that the network meshes are sufficiently wide. Obviously, upon contact with the aqueous external release environment (gastro-intestinal (G.I) fluids), the stabiliser action ends and drug nano-crystals or amorphous state tend to come back to the more stable form (re-crystallisation), i.e. to the macro-crystals condition, according to different kinetics depending on the carrier and drug type. Accordingly, the release process takes place as the drug were characterised by a decreasing solubility [4]. Interestingly, despite the re-crystallisation phenomenon, the average solubility and, thus, bioavailability of the drug are neatly increased [7].
Whereas the mathematical modelling of drug release from an ensemble of poly-disperse polymeric particles have been matched in literature [4], few modelling attempts have been performed on the combination of drug release, absorption, elimination and metabolism (ADME) [8, 9]. The reasons for this probably rely on the mathematical difficulties connected to this task. However, as recently pointed out by Siepmann [10], one of the major challenges to be addressed in the future is the combination of mechanistic theories describing drug release out of the delivery systems with mathematical models quantifying the subsequent drug transport within the human body in a realistic way. Accordingly, the aim of this paper is to present a mathematical model able to account for 1) the in vivo drug release from an ensemble of polymeric particles containing a drug in the amorphous and/or nano-crystalline condition, 2) the simultaneous drug absorption from the G.I. mucosa and 3) the final accumulation/elimination/metabolism in the blood. The proposed mathematical model is applied to study the in vitro and in vivo release of a poorly water soluble drug (vinpocetine) from a system realised by co-grinding for three hours micronized crosslinked polyvinilpirrolidone (PVP-clm) and vinpocetine (w/w ratio 4:1). Indeed, preliminary in vivo tests on rats proved the efficacy of this system in improving the bioavailability of vinpocetine [11].
2. EXPERIMENTAL SECTION
2.1 Materials
Vinpocetine, a kind gift from Linnea SA (Riazzino-Locarno, CH), is a semi-synthetic derivative of the Vinca minor L. alkaloid vincamine [12]. VIN is base-type drug (pKb = 7.1) whose solubility in buffer (0.2 M KH2P04/0.2 M NaOH (pH 7.4) at 37°C) is 1.6 g/cm3 [13]. It has been shown to improve cerebral circulation and metabolism in the treatment of various types of cerebrovascular circulatory disorder, e.g. cerebral infarction, cerebral haemorrhage residual etc. It is mainly used as oral dosage forms, usually in tablets, containing 5 mg of active ingredient, with a daily dosage regimen that can vary between 5mg to 20mg for three consecutive days [14]. However, existing formulations exhibit poor bioavailability (~6.7%) [15, 16] and poor absorption [17] due to its scarce aqueous solubility, wettability and extensive metabolism during first pass. Micronized crospovidone (PVP-clm) was purchased by BASF/Euphar (Milano, Italy). All other chemicals, of analytical grade, and solvents of HPLC grade, were provided by Carlo Erba (Milan, Italy). The delivery system was prepared by co-grinding for three hours the drug and the polymer (1:4 w/w ratio) in a planetary mill Fritsch P5 (Pulverisette, Contardi Fritsch s.r.l., Milan, Italy) [11].
2.2 In vitro test
Release tests, performed in triplicate, were led in 250 cm3 of 0.2 M KH2P04/0.2 M NaOH (pH 7.4) at 37°C. Two different release tests were performed. In the first case, at time zero, 25 mg of the co-ground system (this corresponds to 5 mg of vinpocetine) were added to the release environment while, in the second case, 12.5 mg of the co-ground system (this corresponds to 2.5 mg of vinpocetine) were added to the release environment. Uniformity conditions were ensured by means of an impeller (rotational speed 200 rpm). The use of a fibre optic apparatus (HELLMA, Italy), connected to a diode array spectrophotometer (ZEISS, Germany, wavelength 270.19 nm), allowed the determination of vinpocetine concentration without perturbing the release environment (each release test lasted 180 minutes). Moreover, this methodology allowed to easily overcome the problem connected to drug concentration measurement in presence of a dispersion of solid particles. Indeed, the UV spectrophotometer, recording the UV absorption spectrum in the wavelength range 210-620 nm, can automatically subtract the scattering absorption due to the polymeric particles from the vinpocetine maximum UV absortion occurring at 270.19 nm. As the scattering effect does not depend on wavelength in the wavelength range considered, it was evaluated at 500.49 nm, i.e very far from 270.19 nm.
2.3 In vivo test
10 mg vinpocetine dose (this corresponds to 50 mg of co-ground system) was orally administered to eight healthy male volunteers, aged between 25 and 50 years and weighing on average 75 kg. The test was subdivided in two steps. In the first step, the co-ground system was administered two five volunteers while the second step regarded the last three volunteers and was performed 4 months later. Written informed consent was signed by each subject participating in the study. The research followed the tenets of the Declaration of Helsinki promulgated in 1964 and was approved by the institutional human experimentation committee. All the volunteers had normal hepatic and renal function. All subjects were asked not to take any drugs before and to fast from 12 hours before administration until lunch on the treatment day. They were also not allowed to smoke, not to take coffee or alcoholic beverages 12 hours before and 48 hours after the study drug administration. The subjects were all given a standard lunch 5.5 hours after the dosing and were allowed to drink water during the treatment period. Blood samples (5 ml) were drawn at 0.5, 1, 2, 4 and 6 hours after administration for the first five volunteers while blood samples (5 ml) were drawn at 0.25, 0.5, 1, 1.5, 2, 3, 4 and 6 hours after administration for the remaining three volunteers. Each sample was collected in a heparinised tube; the plasma was then immediately separated by centrifugation (at 4000 rpm for 45 min) and stored at -20°C until analysis. The determination of vinpocetine concentration in the plasma implied the addition of 600 l methanol to 200 l plasma. This mixture was vortexed for 10 min. After centrifugation (5000 rpm for 6 min), 5 l of the organic solution were assayed by a validated HPLC analysis with mass spectrometry detection [18]. HPLC system consisted of a Varian LC212 with a 500-MS IT mass detector. The chromatographic separation was conducted at room temperature, using a Varian C 18 Polaris column (3 m, 2.0 x 50 mm). The mobile phase was composed of water with 0.1% formic acid (solvent A) and acetonitrile (solvent B). Isocratic conditions were used with A 57: B 43, total run time was 3 min. The flow rate was 200 l/min. MS conditions: ESI (positive mode), needle voltage 5350 V, drying gas temperature was 400° C, capillary voltage was set to 100 V and RF loading was set to 100%, nebulizer gas pressure was 25 psi; drying gas pressure was 15 psi. The detector was set to monitor m/z= 290-390. The calibration curve for vinpocetine ranged from 14 to 200 ng/ml (plasma). The limit of quantification was 2 ng/ml. The precision and accuracy were under 3% for all calibration points.
3. MATHEMATICAL MODELLING
3.1 In vivo drug release, absorption, distribution, metabolism and elimination
The complete description of all the phenomena involved in the release kinetics from drug loaded particulate systems is not a trivial task as release kinetics is ruled by many phenomena such as matrix swelling and erosion, drug dissolution, re-crystallisation and diffusion, drug-matrix network interactions, drug distribution and concentration inside the matrix and finally, particle size distribution. The scenario is, then, made more complex when the modelling aim is not limited to the description of the release kinetics in the release environment (G.I. fluids), but it also has to describe drug absorption (by the G.I. tract mucosa), distribution (among blood, tissues and organs), metabolisation and elimination, i.e, the so called ADME processes. Indeed, the mathematical model must account for drug permeation through cellular membranes and distribution/elimination in the blood, tissues and organs.
In the light of process complexity, model building could be based on the following simplifying assumptions [4, 5, 19]: 1) GI tract is considered as a well stirred environment (uniform drug concentration in its liquid volume), 2) drug release in the GI fluids is substantially equal to in vitro drug release (to make this assumption as reasonable as possible, the definition of more and more sophisticated in vitro techniques to test the drug release is required) 3) drug solubility (Cs) in the release environment (GI fluid) and drug permeability (P) are constant along the GI tract, 4) even if more complex approaches could be considered, for the sake of simplicity, drug pharmacokinetics is represented by two “external” compartments, blood and tissues, an the central one, i.e the GI environment, 5) the polymeric powder is made up by spherical particles that do not undergo significant erosion. In addition, the particle size distribution in the dry state (this corresponding to the initial powder condition), is supposed to be conveniently described by the Weibull equation [20], even if, in principle, any distribution equation could be used:
										(1)
where Rp and Rmin are the generic particle radius and the minimum particle radius, respectively,  and  are two parameters regulating the Weibull size distribution, while V0 and V are the total volume occupied by the ensemble of polymeric particles and the volume occupied by particles having a radius lower than or equal to Rp, respectively.
In order to describe the whole release process, two mass balances, referred to the solvent (water or GI fluid) uptake and to the drug release, respectively, must be taken into consideration and solved for all the particles. Although the model accounts for particle volume increase due to polymer swelling, it assumes that the drug diffusion process does not reflect in any volume variation. Accordingly, the solution of the problem may be achieved by first solving the solvent mass balance and then, once the solvent concentration profile is known inside each particle, by solving the drug mass balance. Due to the viscoelastic nature of the polymer/solvent system, solvent uptake needs to be described according to a not-fickian approach. Among the huge variety of models proposed in the past [4], that proposed by Camera-Roda and Sarti provides a simple but reasonable way to account for the relaxation of viscoelastic materials in the analysis of diffusional problems [21]. This theory assumes that the global solvent flux J can be subdivided into two contributions:
J = Jf + Jr											 (2)
where Jf represents the fickian contribution to the solvent flux, while the second term Jr is the relaxation contribute representing the viscoelastic nature of the polymeric-solvent system. In a spherical coordinate system, Jf and Jr read:
											 (3)
											 (4)
where Cp represents solvent concentration at the radial position R, t is the time, D0 is the solvent diffusion coefficient in the dry polymeric network, Dr is the diffusion coefficient of the not-fickian flux while  is the relaxation time characteristic of the polymer–solvent system. Dr and  dependence on local solvent concentration is given by:
										 (5)
											 (6)
where Cpeq is the solvent concentration in the completely swollen polymeric network (thermodynamic equilibrium), eq and Deq are the relaxation time and the solvent diffusion coefficient in equilibrium conditions (indeed, solvent diffusion coefficient, according to eqs.(2)-(4), is given by Dr + D0 and, at equilibrium, Dr = Deq – D0 according to eq(5)), respectively, f and g are two model parameters. For each particle class “j” (particles having the same radius Rp) into which the continuous particles size distribution (see eq.(1)) can be subdivided in, solvent mass balance reads:
										(7)
Assuming that no volume variations occur upon polymer-solvent mixing (ideal behaviour), particles volume increase and solvent concentration profile inside particles are evaluated on the basis of a microscopic (eq.(7)) and a macroscopic mass balance made up on each spherical shell (control volume [22]) into which the generic particle can be subdivided in (for each particle class “j” we have Nv control volumes). The macroscopic mass balance simply states that, at each time, the volume of the generic spherical shell is given by the sum of the polymer volume (constant with time) and the volume of the solvent contained in the spherical shell (local solvent amount). Obviously, local solvent volume depends on local solvent concentration that is time dependent. The spherical shell radius Rj depends on local solvent concentration according to:
								(8)
where s and Cpj are, respectively, solvent density and local concentration while and  represent the radii of the inner and outer spherical shells sandwiching of the spherical shell characterised by radius Rj. In addition,  and  indicate, respectively, the values of  and  when solvent concentration is zero (shrunken, dry condition).
Eqs.(7) are numerically solved [22] assuming that, initially, particles are solvent free, that solvent flux, for symmetry reasons, is zero in the particle centre and solvent concentration at the particle surface is ruled by: 
			j =1, 2, …..Nc				(9)
where Nc is the number of classes into which the continuous particle size distribution (eq.(1)) has been subdivided in and Rpj is the time dependent radius of particles belonging to class “j”. Eq.(9) states that at the particle surface (R = Rpj(t)), solvent concentration does not immediately reach the equilibrium value (Cpeq) but its increase depends on the local relaxation time  defined by eq.(6).
The drug release process can be solved by writing a proper mass balance for each of the Nc classes into which the particle size distribution can be subdivided in:
			j =1, 2, ….. Nc		(10)
					j =1, 2, ...... Nc		(11)
								           (11’)
						j =1, 2, ….. Nc		(12)
					j =1, 2, ….. Nc		(13)
										(14)
where Cj is the concentration of the dissolved drug evaluated at radius Rj inside the particles of the jth class, ,  and are, respectively, the concentrations of the not dissolved drug in the amorphous, nano-crystalline and macro-crystalline state evaluated at radius Rj inside the particles of the jth class, D is the drug diffusion coefficient (depending on Cpj(Rj)), K rules the drug dissolution process inside each particle and it is independent on drug status (amorphous, nano- and macrocrystals) [23],  and  are, respectively, the drug nano- and macro-crystal solubility, Vr is the volume of the release environment and Cr is the drug concentration in the release environment. Eqs.(11’) expresses, according to the theory of Nogami [23], the reduction of amorphous drug solubility at the solid-liquid interface. Indeed, upon dissolution, the amorphous phase re-crystallises on the solid surface in form of macro-crystals and the original amorphous surface is replaced by the macro-crystalline one. Consequently, amorphous drug solubility at the solid-solvent interface () reduces from the initial value  to the final one  according to the exponential law represented by eq.(11’). While Kr rules drug re-crystallisation inside the particles, Krb rules drug re-crystallisation in the release environment and Mc is the drug amount re-crystallised in the release environment. It can be noted that in the drug mass balance referred to the jth particle class (Eq. (10)), four contributes appear in the right hand side term. While the first one is related to the diffusion process, the following three represent, respectively, the dissolution process of amorphous, nano-crystals and macro-crystals drug. The dissolution process of the not dissolved drug in its three possible conditions (amorphous, nano-crystalline and macro-crystalline) is represented by eqs.(11)-(13), whose right hand side term is set to zero when ,  and  disappear (solid drug has completely solubilised).
As drug diffusion coefficient in the polymeric network mainly depends on the local solvent concentration, the D dependence on Cp suggested by Peppas – Reinhart [24, 25] is considered: 
									(15)
where Dds is the drug diffusion coefficient in the pure solvent, B is a model parameter while  is the local polymer volume fraction and s is the solvent density. Eq.(10) is numerically solved [22] assuming that the initial drug concentration in the release environment is zero, that, initially, no dissolved drug exists inside the particles (only solid or amorphous drug can be found in the polymeric network) and that the solid and/or amorphous drug concentration is uniform inside the particles (the model could easily account for more complex drug distributions). Finally, for symmetrical reasons, drug flux in the particles centre is set to zero and the usual drug partitioning condition at the particle/solvent interface is considered (Kp is the drug partition coefficient).
In order to complete the model, the equations related to drug absorption, distribution and elimination must be considered. For this purpose, it is convenient to refer to Figure 1 which reports the physical situation that the model mimics.

Figure 1. Schematic representation of drug release (from drug loaded polymeric particles), absorption, elimination/metabolism and exchange with tissues.

Drug concentration in the blood (Cb) increases due to the drug flux coming from the G.I. tract fluid and crossing the G.I mucosa (). At the same time, Cb decreases because of the elimination/metabolism process (-) and it is affected by the distribution within the surrounding tissues/organs (; CT = drug concentration inside tissues/organs). Thus the differential equation accounting for Cb variation is:
							(16)
where t is time and Vb, A and P are, respectively, the blood compartment volume, the GI tract geometrical surface (without considering the presence of villi and microvilli that would considerably increase the surface) and the average apparent permeability of the G.I. tract. The adjective “apparent” is due to the fact that P does not refer to the real absorption surface of the G.I. but to the geometrical one. Nevertheless, as the product AP is equal to the product of real permeability and surface area, in principle, there is no need for the exact knowledge of real A and P. Analogously, the variation of drug concentration inside tissues/organs CT is given by:
										(16)
where VT is the tissues/organs volume while  and  are, respectively, the direct and reverse exchange constants between the blood and the tissues/organs compartments. The above mentioned equations can be conveniently re-written as:
							(18)
										(19)
where the absorption constant is defined by Ka = AP/Vb, the elimination constant is defined by , the exchange constants are defined by  and  while f = Vb/VT.
In order to close the balance between the unknowns (drug concentration profile inside each particles class, Cr, Cb, and CT) and the equations, we need one more equation. This equation is an overall mass balance ensuring that the sum of the drug mass present in the G.I. fluid (VrCr), in the delivery system (), in the blood (VbCb), in tissues/organs (VTCT) plus the amount of drug re-crystallised in the release environment (Mc) and that eliminated/metabolised in the blood (Me) is always equal to the initial drug mass administered, i.e. drug dose (M0):
													(20)
										           (20’)
where Vr is the release environment volume and Npj indicates the number of particles belonging to the “j” class. While eqs.(7) are solved according to the fully implicit control volume method [22] assuming Nv = 10, Nc = 20 and a time step of 2.5 s, ordinary differential equations (eqs. (18), (19)) are solved by considering an implicit finite difference approach.

3.2 Evaluation of model parameters
As the presented model needs many parameters, the majority of them have to be determined in advance in order to minimise the number of fitting parameters. Accordingly, the parameters ruling solvent uptake are set according to previous findings [4]: Cpeq = 0.31 g/cm3, Deq = 10-7 cm2/s, D0 = 10-10 cm2/s, g = 51.75, eq = 0.35 and f = 12. Particle size distribution can be described by eq.(1) assuming  = 60*10-4 cm,  = 1 and 10-4 cm ≤ Rp ≤ 140*10-4 cm [11]. Vinpocetine physical properties were determined elsewhere [11] and are reported in tab. 1. While, for the sake of simplicity, vinpocetine partition coefficient (Kp) is set to 1, its diffusion coefficient in water at 37°C is evaluated according to the well known Stokes-Einstein equation (Dds = 4.7*10-6 cm2/s). In addition, the parameter B of eq.(15) is set to one [26].
Table 1. Vinpocetine physicochemical characteristics. Mw is the drug molecular weight, pKb indicates the pH value for vinpocetine dissociation,  is the solubility, s and l are, respectively, the solid and liquid density, Tm and Hm are, respectively, the melting temperature and enthalpy, Cpls is the difference between the specific heat at constant pressure in the liquid and solid state, sl is the solid-liquid vinpocetine surface tension, lv is the liquid-vapour vinpocetine surface tension, sv is the solid-vapour vinpocetine surface tension, H2O and CH2I2 are, respectively, the water and diiodemethane contact angles on solid vinpocetine [11].
Mw	pKb	(g/cm3) (37°C, H2O, pH = 7.4)
350	7.3	1.6 
s(Kg/m3) 	l(Kg/m3) 	Tm(°C) 	Hm(J/Kg) 	Cpls(J/Kg°K)
1268	1217	149.6	94600	374
sl(mJ/m2) 	lv(mJ/m2) 	sv(mJ/m2) 	H2O(°)	CH2I2(°)
8.9	29.5	38.4	81	33

Finally, the determination of vinpocetine nanocrystals solubility () is needed. Unfortunately, this information can not be experimentally retrieved because of many factors among which the Ostwald ripening [4] is one of the most important. This phenomenon consists in larger crystal growth at the expense of smaller ones and the asymptotic reduction of solution solubility. Indeed, the dissolution of small crystals, characterised by higher solubility, renders the liquid phase over-saturated with respect to big crystals, characterised by lower solubility. Thus, part of the solute leaves the solution and provokes bigger crystals growth. This is the reason why the estimation of  can be performed only on a theoretical basis. The starting point is the thermodynamic equation representing the equilibrium between a liquid and a nano-crystalline solid phase, in the hypothesis that the liquid phase does not spread in the solid one:
										(21)
where d and Xd are, respectively, the drug activity coefficient and solubility (molar fraction) in the liquid phase,  is the drug fugacity in the reference state,  is the drug fugacity in the nano-crystalline solid state while Msw is the solvent molecular weight. Assuming  as the fugacity of pure drug in the state of under-cooled liquid at the system temperature (T) and pressure, eq.(21) becomes [4]:
				(22)
where Tmr and Hmr are, respectively, nanocrystals melting temperature and enthalpy. The determination of Tmr and Hmr relies on the relations existing among Tmr, Hmr and the nanocrystals radius Rnc [4]:
					(23)
							(24)
where Xncr indicates the mass fraction of nano-crystals constituting the solid phase (the remaining part of the solid phase is represented by amorphous drug that can not melt). While eq.(23) is a modification of the Brun theory [27], the second one (eq.(24)) is the equation of Zhang [28]. The simultaneous, iterative, numerical solution of eqs.(23)-(24) allows the determination of the Tmr and Hmr dependence on Rnc once Xncr is fixed (see Figure 2a and 2b). On this basis and knowing that Xd = 5.27* 10-8 mol/l (= 1.6 g/ml), it is possible estimating d = 911460. Assuming that d does not modify with Rnc, it is possible to estimate the dependence of vinpocetine nanocrystals solubility on Rnc according to eq.(20) (see Figure 3). Figures 2-3 make clear that the variation of nano-crystals mass fraction (Xncr) does not sensibly affect the trend of vinpocetine melting enthalpy (Hmr), melting temperature (Tmr) and solubility () versus nano-crystals radius (Rnc).

 




Figure 2b. Vinpocetine melting temperature (Tmr) reduction with nano-crystals radius Rnc for different values of the nano-crystals mass fraction (Xncr)


Figure 3. Dependence of vinpocetine solubility () on the dimension of nanocrystals curvature radius (Rnc) for different values of the nano-crystals mass fraction (Xncr).

4. RESULTS
Due to model complexity, the study of the in vivo behaviour of our co-ground system needs to fit in advance the model to in vitro data in order to determine three very important model parameters, namely the amorphous vinpocetine solubility (), dissolution (K) and re-crystallisation (Kr, Krb) constants. Essential prerequisite for in vitro data fitting is the determination of drug condition inside the co-ground system, i.e the fraction of vinpocetine present in form of macro-crystals, nano-crystals and amorphous drug. On the basis of the thermal behaviour of the co-ground system (obtained by differential scanning calorimeter analysis [11]) and the data shown in Tab. 1, eqs.(23)-(24) can be iteratively solved to determine the mass fraction of nano-crystals (Xncr). In particular, we find that vinpocetine macro-crystals are absent (no melting peak appeared at 149.6 °C) while the mass fraction (Xncr) of nanocrystalline vinpocetine is 0.17, the remainder being amorphous vinpocetine (0.83). As the average nano-crystalline radius Rnc is equal to 5 nm, it can be concluded that vinpocetine nano-crystals solubility  is approximately 2.4 g/cm3 (see Figure 3). Knowing the information on the vinpocetine state in the co-ground system, drug concentration in the particles (= 211060 g/cm3 ;  = 31537 g/cm3 ;  = 0 g/cm3; j = 1, ….. N) and assuming the values of all other model parameters as previously set (see paragraphs 2.2 and 3.2), the model can be fitted to in vitro data referring to 5 mg dose (open circles in figures 4). Obviously, at this stage, model fitting is performed setting all the pharmacokinetic constants equal to zero as no ADME processes take place in vitro test. Figure 4 reports the comparison between model best fitting (solid thick line) and the in vitro experimental results referring 5 mg dose (open circles). It can be seen that the fitting is satisfactory as also proved by the statistical F-test (F(1,10,95) < 945). Fitting parameters read Kr = Krb = 0, K* = 1000 ± 100 g/cm3. Unfortunately, the absence of macro-crystals and the relatively small fraction of nano-crystals makes parameters K and Csa highly correlated (see eqs.(11)-(13)). Accordingly, we can estimate only their product setting K = 1 s-1 and letting  to change during the fitting procedure. However, the correctness of these findings is proved by the comparison between model prediction (solid thin line in figure 4) and release data referring to 2.5 mg dose (filled circles in figure 4). Model prediction is obtained by assuming all the parameters coming from model fitting to 5 mg dose data except for the amount of the co-ground system that is one half. Relying on these findings, it is possible to fit the model on in vivo data assuming that the volume of the release environment Vr (GI fluids) is equal to 250 cm3 [29] and knowing that the dose (M0, see eq.(20)) is equal to 10 mg (this corresponds to 50 mg of the co-ground system). Figure 5a shows, for each one of the eight volunteers considered in this study, the time course of vinpocetine concentration in the blood (Cb) after oral administration of 50 mg of the co-ground system, corresponding to a dose of 10 mg of vinpocetine.

Figure 4. Vinpocetine concentration increases (Cr) in the release environment in in vitro test. Open circles indicate the experimental data referring to a drug dose of 5 mg while filled circles indicate the experimental data referring to a drug dose of 2.5 mg (vertical bars indicate standard error). Solid thick line indicates model best fitting while solid thin line represents model prediction determined on the basis of parameters determined by model fitting to 5 mg dose data.

In order to check its reliability also in the in vivo case, the model is fitted on the experimental subset represented by the first five volunteers (open circles in Figure 5b, sampling at 0.5, 1, 2, 4 and 6 h) and then this fitting is compared with the other experimental subset represented by the remaining three volunteers (filled circles in Figure 5b, sampling at 0.25, 0.5, 1, 1.5, 2, 3 4 and 6 h). In so doing, we can evaluate the general validity of model findings on other, uncorrelated subjects, and we can see model reliability in predicting the vinpocetine blood concentration corresponding to sampling times (0.25, 1.5 and 3 h) different from those used (0.5, 1, 2, 4 and 6 h) for model fitting.
A preliminary fitting procedure led on the first experimental subset (open circles in figure 5b), assuming Vb, VT Ka, Kel, K12 and K21 as fitting parameters, reveals that K12 and K21 are unnecessary as they turn out to be statistically not different from zero. Accordingly, data fitting is repeated assuming Vb, Ka and Kel as fitting parameters. In order to speed up fitting procedure (we are dealing with a mathematical model requiring a heavy numerical solution), model fitting is led fixing Vb and letting Ka and Kel to vary in order to minimise 2.

Figure 5a. Time course of vinpocetine concentration in the blood (Cb) after oral administration of 50 mg of the co-ground system, corresponding to a dose of 10 mg of vinpocetine (17% nanocrystalline and 83% amorphous). Each symbol represents one volunteer whose characteristics are listed in Table 1.

This procedure is repeated for different values of Vb starting from an initial guess determined by fitting the in vivo data referring to the first blood concentration Cb measured at 1, 2 4 and 6 hours, see Figure 5b) by means of a simple Cb exponential decay with time:
											(25)
Basically, this equation assumes that drug elimination is the leading process after 1 hour. Accordingly, Vb first guess is  = (55000 ± 6000) cm3 (we also find that Kel = (0.32 ± 0.04) h-1). Whereas 2 increases for Vb > , it decreases for smaller values up to a critical Vb value after which, further Vb decrease leads to 2 increase. Assuming Vb critical value as the true one, model fitting results in: Vb = 36200 cm3, Ka = (0.11 ± 0.6) h-1 and Kel = (0.5 ± 0.03) h-1. As Figure 5b clearly shows, the fitting (solid line) is accurate, as also indicated by the F-test result (F(1,3,0.95) < 165). In addition, the comparison between model best fitting (solid line) and the second subset of experimental data (gray circles) indicates a general agreement between them also in the case of sampling performed at 0.25, 1.5 and 3 hours

Figure 5b. Time course of vinpocetine concentration in the blood (Cb) after oral administration of 50 mg of the co-ground system, corresponding to a dose of 10 mg of vinpocetine (17% nanocrystalline and 83% amorphous). Open circles indicate the experimental data on which the model was fitted to, while gray circles serve to check the reliability of the model prediction. Model best fitting is represented by the continuous line and vertical bars indicate datum standard error.











average	-	34 ± 9	77 ± 5

5. DISCUSSION
An inspection of Figure 3 reveals that, regardless of nanocrystals mass fraction Xncr, an interesting increase of vinpocetine solubility takes place only for nano-crystals radius smaller than 2 nm. For smaller radii, solubility increases up to around 35 g/cm3 (approximately 22 times that of the original macro-crystalline vinpocetine), this corresponding to the half side of the smallest vinpocetine crystal, ie the crystalline unit cell (~ 0.6 nm) [11]. Although we could not separately determine amorphous vinpocetine solubility () and dissolution constant (K), Figure 3 would suggest that the assumption  ≈ 1000 g/cm3 is not so unreasonable. In addition, for the in vivo fitting, we do not need an exact knowledge of both K and  as, in our case (absence of macro-crystals and predominance of amorphous fraction on the nano-crystalline one), drug dissolution is essentially ruled by the product K* (see eqs.(11)-(13)). In the light of these considerations, we can conclude that a real improvement of vinpocetine solubility occurs essentially when it is reduced to its amorphous state. The results coming from the model fitting on the experimental in vitro data make clear that the vinpocetine re-crystallisation process is very slow as a vanishing Kr value turns out for the description of three hours lasting experiments (Figure 4). Although re-crystallisation will surely occur at longer time points, its importance on in vivo behaviour is very limited as after three hours the predominant part of the absorption process has been completed (see Figure 5a and b).
The value of Vb, neatly bigger than the theoretical blood volume (~ 3250 cm3 for a human being weighing 75 Kg [30]), can be explained by vinpocetine binding to plasma proteins [18]. Vinpocetine elimination constant (Kel = 0.5 h-1) results to be comparable to that of Acetaminophen (0.28 h-1), Gentamicin (0.35 h-1) and Lidocaine (0.43 h-1) while it is neatly bigger than that of Diazepam (0.021 h-1), Digoxin (0.017 h-1) and Theophylline (0.063 h-1) [31]. Finally, the evaluation of the absorption constant (Ka = AP/Vb) allows the estimation of the vinpocetine apparent permeability P as blood volume (Vb) has been determined and the G.I. tract geometrical surface A is around 13116 cm2 [4]. Accordingly we have P ≈ 8*10-5 cm/s, this putting vinpocetine in the class II drugs (poor solubility and good permeability) according to the Amidon bio-pharmaceutics classification [29, 32].
6. CONCLUSION
This work proves that it is possible to build up a mathematical model able to describe the in vivo fate of a drug orally administered. In particular, the proposed model can account for the simultaneous processes of in vivo drug release and ADME processes following the oral administration of a drug dispersed, in form of nano-crystals and amorphous state, inside polymeric particles of different dimensions. For this purpose, the model needs to know information on the polymer and drug physico-chemical properties. In addition, some fitting parameters have to be determined by model fitting to in vitro release data. Once all the parameters are known, it is possible to use the model to predict or, at least, to give a reasonable idea of the effect of the different parameters on the time course of the drug concentration in the blood. Accordingly, this model should be an important tool helping to drive and to focus experimental tests to a fixed target, allowing to save money and time. Future development of this model will regard the variation of both drug solubility and permeability through the GI tract.
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